A single institutional experience: Is epoetin alpha effective in anemic children with cancer?

Pediatric Hematology and Oncology

Volumn 21, Issue 1, 2004, Pages 1-8

  Yilmaz, Deniz ^a,c   Cetingul N ^a   Kantar, M ^a   Oniz H ^b   Kansoy, S ^a   Kavakli, K ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b SSK   (Turkey)

^c Division of Pediatric Hematology   (Turkey)

Author keywords

Anemia; Cancer; Children; Epoetin alpha

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN DETERMINATION; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

ADOLESCENT; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; EPOETIN ALFA; FEMALE; HEMATOLOGIC NEOPLASMS; HEMOGLOBINS; HUMANS; INFANT; MALE; NEOPLASMS;

EID: 0345872392     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010490263281     Document Type: Article

References (14)

1. Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy: a retrospective cohort study. Am J Clin Oncol. 1993;16:22-25.
2. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion. 1995;35:427-430.
3. Ferencz T, Csaki CS, Koos R, et al. Transfusion requirements following chemotherapy in pediatric solid tumors. Erythropoiesis. 1994;5:115-118.
4. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double blind and open label follow-up. Sem Oncol. 1994;21:21-28.
5. Leitgeb C, Pecherstorfer M, Fritz E, Ludwing H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. 1994;73:2535-2542.
6. Ludwig H, Leitgeb C, Fritz E, et al. Erythropoietin treatment of chronic anemia of cancer. Eur J Cancer. 1993;29 A (supp 12):8-12.
7. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alpha on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
8. Bolonaki I, Stiakaki E, Lydaki E. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol. 1996;13:111-121.
9. Porter JC, Leahey A, Polise K, et al. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double blind placebo-controlled trial. J Pediatr. 1996;129:656-660.
10. Beck MN, Beck D. Recombinant erythropoietin in acute chemotherapy induced anemia of children with cancer. Med Ped Oncol. 1995;25:17-21.
11. Varan A, Büyükpamukçu M, Kutluk T, Akyüz C. Recombinant human erythropoietin treatment for chemotheraphy related anemia in children. Pediatrics. 1999;103:E16.
12. Tamary H, Danon YL. Recombinant human erythropoietin in children with cancer. Pediatr Hem Oncol. 1996;13:305-308.
13. Leon P, Jimenez M, Barona P, Sierrasesumaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Ped Oncol. 1998;30:110-116.
14. Macmillan ML, Freedman MH. Recombinant human erythropoietin in children with cancer. J Ped Hem Oncol. 1998;20:187-189.